Home page > Press releases

Authorize the processing of personal data
Edit email address
Invalid email
Email Sent
Authorize the processing of personal data
ARCHIVE PRESS RELEASE
Chiesi Group: performance is up in 2020
09 Março 2021 PRESS
Chiesi Group receives the European marketing authorisation for Trimbow® (beclometasone dipropionate, formoterol fumarate, glycopyrronium) an extrafine formulation fixed triple combination therapy for the treatment of asthma
01 Fevereiro 2021 PRESS
Chiesi Headquarters: an innovative, sustainable and people-friendly “home”, the first building in its category to be certified “LEED Platinum” in Italy. A people-oriented project.
27 Janeiro 2021 PRESS
Il Gruppo Chiesi firma accordo integrativo all’avanguardia sui diritti dei lavoratori
18 Janeiro 2021 PRESS
“Infermieri, a viso aperto”, a photographic project bringing to light the faces and stories of those who help patients every day
14 Janeiro 2021 PRESS
Kaia Health and Chiesi Group Announce Strategic Partnership to Commercialise Kaia COPD Pulmonary Rehabilitation App in European Markets
30 Novembro 2020 PRESS
Chiesi Group receives Diversity Leaders Award 2021
19 Novembro 2020 PRESS
Chiesi launches “The Art of Caring”, a journey in search of the link between Parma, officinal treatments and pharmaceutics
17 Novembro 2020 PRESS
Maria Paola Chiesi received by the President of the Italian Republic for the 2020 Bellisario Award ceremony
15 Outubro 2020 PRESS
Il Gruppo Chiesi accoglie la visita ufficiale del Sottosegretario di Stato Stanislao Di Piazza
28 Setembro 2020 PRESS
We ACT Day 2020: the third edition of Chiesi’s event for a sustainable future
24 Setembro 2020 PRESS
Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH).
21 Setembro 2020 PRESS
Chiesi Group increases support measures and announces new funds for employees, patients and healthcare providers in response to COVID-19 pandemic
30 Março 2020 PRESS
© 2024 CHIESI PAKISTAN
Office # 4, 4th Floor, Askari Corporate Tower, 75/76 D 1, Main Boulevard, Gulberg III, Lahore (Pakistan)
Phone: +92 42 111-244-374
Fax: +92 42 37881602

PHARMACOVIGILANCE

TO REPORT ADVERSE DRUG EVENTS/REACTIONS PLEASE CLICK HERE